Acute inflammation of lacrimal passage

Summary

Acute inflammation of lacrimal passage (MONDO:0004055) is a disease. A subtype of lacrimal apparatus disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acute inflammation of lacrimal passage
Mondo ID	MONDO:0004055
DOID	DOID:6970
SNOMED CT	302900006
UMLS	C0339129
MedGen	572973
Is cancer (heuristic)	no

Disease family

This is a subtype of lacrimal apparatus disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › lacrimal apparatus disorder › acute inflammation of lacrimal passage

Related subtypes (16): lacrimal passage granuloma, eversion of lacrimal punctum, stenosis of lacrimal punctum, stenosis of lacrimal passage, excessive tearing, primary lacrimal atrophy, secondary lacrimal atrophy, lacrimal system cancer, stenosis of lacrimal sac, chronic inflammation of lacrimal passage, dry eye syndrome, IgG4-related dacryoadenitis and sialadenitis, isolated congenital alacrima, disorder of lacrimal gland, nasolacrimal duct disorder, syndromic lacrimal system disorder

Subtypes (1): acute canaliculitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.